Integer Holdings Co. (NYSE:ITGR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Integer Holdings Co. (NYSE:ITGR) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $139.75.

ITGR has been the subject of a number of research analyst reports. Benchmark raised their price objective on Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Citigroup raised their price target on Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. Bank of America upped their price objective on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Piper Sandler reissued an “overweight” rating and issued a $140.00 target price (up from $125.00) on shares of Integer in a report on Friday, October 25th. Finally, KeyCorp upped their price target on shares of Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Blue Trust Inc. lifted its holdings in shares of Integer by 460.4% in the 2nd quarter. Blue Trust Inc. now owns 5,643 shares of the medical equipment provider’s stock worth $658,000 after acquiring an additional 4,636 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in Integer by 3.0% in the third quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider’s stock worth $69,943,000 after purchasing an additional 15,446 shares during the last quarter. Earnest Partners LLC boosted its position in shares of Integer by 3.2% during the second quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock valued at $139,911,000 after buying an additional 37,340 shares during the period. Great Lakes Advisors LLC grew its stake in shares of Integer by 56.7% during the second quarter. Great Lakes Advisors LLC now owns 45,218 shares of the medical equipment provider’s stock valued at $5,236,000 after buying an additional 16,355 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Integer in the third quarter worth approximately $651,000. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Price Performance

NYSE:ITGR opened at $140.50 on Monday. The business’s 50-day simple moving average is $131.38 and its two-hundred day simple moving average is $124.50. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. Integer has a 52 week low of $84.75 and a 52 week high of $142.00. The stock has a market cap of $4.71 billion, a PE ratio of 43.36, a P/E/G ratio of 2.01 and a beta of 1.09.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm had revenue of $431.42 million for the quarter, compared to analysts’ expectations of $440.59 million. During the same quarter last year, the business posted $1.27 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, analysts forecast that Integer will post 5.33 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.